Debt-to-equity of CRISPR Therapeutics AG from 30 Jun 2017 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
CRISPR Therapeutics AG quarterly Debt-to-equity in % history and change rate from 30 Jun 2017 to 30 Sep 2025.
  • CRISPR Therapeutics AG Debt-to-equity for the quarter ending 30 Sep 2025 was 18%, a 0.34% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

CRISPR Therapeutics AG Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 18% 0% +0.34% 30 Sep 2025
Q2 2025 17% -1% -6.5% 30 Jun 2025
Q1 2025 17% -2% -10% 31 Mar 2025
Q4 2024 17% -3% -17% 31 Dec 2024
Q3 2024 17% -3% -15% 30 Sep 2024
Q2 2024 19% -2% -9.8% 30 Jun 2024
Q1 2024 19% 0% -2.4% 31 Mar 2024
Q4 2023 20% +2% +10% 31 Dec 2023
Q3 2023 21% +3% +20% 30 Sep 2023
Q2 2023 21% +5% +36% 30 Jun 2023
Q1 2023 20% +6% +46% 31 Mar 2023
Q4 2022 18% +6% +54% 31 Dec 2022
Q3 2022 17% +6% +59% 30 Sep 2022
Q2 2022 15% +5% +48% 30 Jun 2022
Q1 2022 14% +3% +30% 31 Mar 2022
Q4 2021 12% 0% +1.6% 31 Dec 2021
Q3 2021 11% -2% -17% 30 Sep 2021
Q2 2021 10% -5% -34% 30 Jun 2021
Q1 2021 10% -8% -43% 31 Mar 2021
Q4 2020 12% -10% -47% 31 Dec 2020
Q3 2020 13% -14% -53% 30 Sep 2020
Q2 2020 15% -13% -46% 30 Jun 2020
Q1 2020 18% -10% -35% 31 Mar 2020
Q4 2019 22% -5% -19% 31 Dec 2019
Q3 2019 27% -4% -12% 30 Sep 2019
Q2 2019 28% -10% -27% 30 Jun 2019
Q1 2019 28% -16% -37% 31 Mar 2019
Q4 2018 27% -24% -47% 31 Dec 2018
Q3 2018 31% -21% -41% 30 Sep 2018
Q2 2018 39% -44% -53% 30 Jun 2018
Q1 2018 44% 31 Mar 2018
Q4 2017 51% 31 Dec 2017
Q3 2017 52% 30 Sep 2017
Q2 2017 83% 30 Jun 2017
* An asterisk sign (*) next to the value indicates that the value is likely invalid.